退伍军人健康管理局微观血尿患者膀胱癌发病率研究
本研究基于退伍军人健康管理局与Medicare链接数据(2015-2024),回顾性分析267,133例新发微观血尿患者,发现2年内膀胱癌累积发病率为1.5%,膀胱镜检查完成率为11.9%。年龄、男性、吸烟史和≥25 RBC/hpf与膀胱癌诊断相关,基于模型的风险预测优于现行AUA指南分类。
要点
- 微观血尿患者2年内膀胱癌累积发病率仅1.5%,膀胱镜检查完成率11.9%。
- 年龄、男性、吸烟史和≥25 RBC/hpf与膀胱癌诊断独立相关。
- 模型预测膀胱癌的AUC为0.63,优于AUA指南的0.52,可细化高风险患者分层。
核心结论
- 利用常规临床人口学因素可估计微观血尿患者的个体化膀胱癌风险。
- 现行AUA指南风险分类缺乏精细度,尤其在「高风险」患者中。
研究设计与样本
- 回顾性队列研究,使用2015-2024年退伍军人健康管理局与Medicare链接数据。
- 纳入267,133例≥18岁新发微观血尿患者,主要结局为索引尿检后2年内新发膀胱癌诊断。
主要发现
- 2年内膀胱镜检查完成累积发生率为11.9%(95% CI 11.7, 12.0)。
- 2年内新发膀胱癌累积发生率为1.5%(95% CI 1.4, 1.5)。
- 调整死亡竞争风险后,年龄较大、男性、吸烟史和≥25 RBC/hpf与膀胱癌诊断相关。
- 膀胱癌预测模型ROC AUC为0.63,优于AUA指南的AUC 0.52(P < .001)。
关键数值与推荐
- AUA风险分类用于分层比较,模型预测可进一步估计AUA「高风险」患者的风险。
临床怎么用
- 可利用年龄、性别、吸烟史和血尿程度等常规因素个体化评估膀胱癌风险。
- 对AUA高风险患者可结合模型进一步风险分层,辅助决策是否行膀胱镜评估。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Microhematuria (MH) may be a sign of underlying genitourinary pathology, but diagnoses of bladder cancer (BC) are rare among those who complete evaluations. This study determines the incidence of BC in a large cohort of patients with MH, assesses the diagnostic potential of current guideline recommendations, and characterizes the relative risks of clinicodemographic factors to inform the need for MH evaluation. MATERIALS AND METHODS: This retrospective cohort study used Veterans Health Administration and Medicare-linked data from 2015 to 2024 and included patients ≥ 18 years diagnosed with de novo MH. The main outcome was a new BC diagnosis within 2 years of index urinalysis with MH. Patients were stratified by AUA risk categories to compare guideline-based risk classification with model-based estimation. The Fine-Gray method was used to estimate adjusted associations between clinicodemographic characteristics and incident BC, accounting for the competing risk of death. RESULTS: Among 267,133 patients with MH, the 2-year cumulative incidences of cystoscopy completion and a new BC diagnosis were 11.9% (95% CI 11.7, 12.0) and 1.5% (95% CI 1.4, 1.5), respectively. Older age, male sex, smoking history, and ≥ 25 RBC/hpf were associated with a new BC diagnosis when adjusted for competing risk of death. Performance of our BC prediction model was better (ROC AUC = 0.63) than that of the current AUA guidelines (AUC = 0.52, P < .001) and allowed for further risk-estimation of patients designated "high risk" by AUA criteria. CONCLUSIONS: Estimation of patient-level MH-related BC risk is possible with readily available clinicodemographic factors. Current approaches lack nuance, particularly among "high-risk" patients. Precision approaches that use relative risk-factor weights and/or novel diagnostic tools may improve individualized decision-making for evaluation.
引用
- Matulewicz RS, Gold SA, Nicholson A, et al. Bladder Cancer Incidence in Patients With Microhematuria at the Veterans Health Administration. J Urol. 2026. PMID: 42747946. doi:10.1097/JU.0000000000005312
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。